Company overview
ImmuneOnco Biopharmaceuticals (Shanghai) Co.,Ltd., founded in June 2015 in Zhangjiang High-Tech Park of Shanghai, China, is an early-stage biopharmaceutical company dedicated to development and commercialization of novel cancer immunotherapeutics that reverse cancer cell-induced immune inhibition and actively eradicate cancer cells.
News Center
-
09-062021ImmuneOnco：Clinical Research Application for IMM27M was accepted by the National Medical Products Administration (NMPA)On September 1, 2021, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") an......See details
-
08-262021ImmuneOnco Received NMPA Authorization to Proceed with 3 Phase Ib/IIa Clinical Trials of IMM01 Combined with Azacytitin, Rituximab and InetetamabAugust 25, 2021, Shanghai, China ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. ( hereinafter referred to as "Immune......See details
-
08-242021ImmuneOnco received FDA approval of IMM2902 as an Investigational New Drug (IND) in the United StatesAugust 21, 2021, Shanghai, China. ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "Immune......See details